ObjectiveTo explore the clinical efficacy and safety of mycophenolate mofetil (MMF) combined with tripterygium glycosides for the treatment of patients with idiopathic membranous nephropathy. MethodsA total of 42 patients with idiopathic membranous nephropathy were randomly divided into control group and observation group, with 21 cases in each group. The control group was treated with prednisone combined with MMF, and the observation group was treated with prednisone combined with MMF and tripterygium glycosides. Both groups were treated for 6 months. The 24-hour urine protein quantitation, serum albumin level, serum creatinine level, cholesterol level, complete remission rate, total effective rate and adverse reactions were compared between the two groups. ResultsThe complete remission rates were 38.10% in the control group and 47.62% in the observation group after 6 months of treatment, and there was no significant difference between the two groups (P＞0.05). The total effective rate in the observation group(90.48%) was significantly higher than that in the control group (61.90%), and the difference was statistically significant (P＜0.05). After treatment, the 24-hour urine protein quantitation, serum albumin level, serum creatinine level and cholesterol level of the two groups were significantly improved, and the improvements in the observation group were better than those in the control group, and the difference was statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment (P＞0.05). ConclusionMycophenolate mofetil combined with tripterygium glycosides for the treatment of patients with idiopathic membranous nephropathy has higher total effective rate, which can improve indicators as for the 24-hour urine protein quantitative more effectively.

无